Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoADAURA
2022-502606-33-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Major pathological response (MPR). Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502606-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502606-33-00.